Patents by Inventor Stanley T. Crooke

Stanley T. Crooke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7695902
    Abstract: Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2?-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates.
    Type: Grant
    Filed: February 20, 2002
    Date of Patent: April 13, 2010
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Patent number: 7666588
    Abstract: The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: February 23, 2010
    Assignee: Ibis Biosciences, Inc.
    Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, Lawrence B. Blyn, Thomas A. Hall, Yun Jiang, James C. Hannis, Neil White, Vivek Samant, Mark W. Eshoo, Jared J. Drader
  • Publication number: 20100041047
    Abstract: The present invention provides, inter alia, methods of selecting a single-stranded oligomeric compounds for inhibiting RNA expression, methods of generating double-stranded oligomeric compounds, methods of identifying optimized double-stranded oligomeric compounds, methods of selecting optimized single-stranded oligomeric compounds, methods of selecting optimized double-stranded oligomeric compounds, methods of identifying multifunctional oligomeric compounds, methods for optimizing target region selection for modulation of RNA expression, methods of optimizing expression modulation of RNA, and the like. The present invention further provides oligomeric compounds, 8-80 nucleobases in length targeted to a target RNA, wherein said oligomeric compound hybridizes to said target RNA and inhibits RNA levels by at least 50% in both single-stranded and double-stranded forms, and multifunctional oligomeric compounds.
    Type: Application
    Filed: July 29, 2009
    Publication date: February 18, 2010
    Inventors: Timothy Vickers, Seongjoon Koo, C. Frank Bennett, Stanley T. Crooke, Nicholas M. Dean, Brenda F. Baker
  • Patent number: 7629321
    Abstract: Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2?-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: December 8, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Publication number: 20090280471
    Abstract: The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.
    Type: Application
    Filed: December 5, 2003
    Publication date: November 12, 2009
    Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, Lawrence B. Blyn, Raymond Ranken, Thomas A. Hall
  • Publication number: 20090270486
    Abstract: The present invention provides polynucleotides encoding human RNase III and polypeptides encoded thereby. Methods of using said polynucleotides and polypeptides are also provided.
    Type: Application
    Filed: December 22, 2008
    Publication date: October 29, 2009
    Applicant: Isis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Publication number: 20090239224
    Abstract: The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases.
    Type: Application
    Filed: December 2, 2008
    Publication date: September 24, 2009
    Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, Lawrence B. Blyn, Thomas A. Hall, Yun Jiang, James C. Hannis, Neill White, Vivek Samant, Mark W. Eshoo, Jared J. Drader
  • Publication number: 20090182511
    Abstract: The present invention provides methods for rapid forensic analysis of mitochondrial DNA and methods for characterizing heteroplasmy of mitochondrial DNA, which can be used to assess the progression of mitochondrial diseases.
    Type: Application
    Filed: October 30, 2007
    Publication date: July 16, 2009
    Applicant: IBIS BIOSCIENCES, INC.
    Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, Lawrence Blyn, Thomas Hall, Yun Jiang, James C. Hannis, Neill White, Vivek Samant, Mark W. Eshoo, Jared James Drader
  • Publication number: 20090156526
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds.
    Type: Application
    Filed: October 17, 2006
    Publication date: June 18, 2009
    Applicant: ISIS Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Stanley T. Crooke
  • Publication number: 20090148829
    Abstract: The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.
    Type: Application
    Filed: October 30, 2007
    Publication date: June 11, 2009
    Applicant: IBIS BIOSCIENCES, INC.
    Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, Lawrence Blyn, Ray Ranken, Thomas A. Hall
  • Patent number: 7491524
    Abstract: The present invention provides polynucleotides encoding human RNase III and polypeptides encoded thereby. Methods of using said polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: February 17, 2009
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Publication number: 20080311558
    Abstract: The present invention provides methods of: identifying pathogens in biological samples from humans and animals, resolving a plurality of etiologic agents present in samples obtained from humans and animals, determining detailed genetic information about such pathogens or etiologic agents, and rapid detection and identification of bioagents from environmental, clinical or other samples.
    Type: Application
    Filed: October 9, 2007
    Publication date: December 18, 2008
    Applicant: Isis Pharmaceuticals, Inc.
    Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke
  • Patent number: 7432249
    Abstract: Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2?-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: October 7, 2008
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Patent number: 7432250
    Abstract: Oligomeric compounds including oligoribonucleotides and oligoribonucleosides are provided that have subsequences of 2?-pentoribofuranosyl nucleosides that activate dsRNase. The oligoribonucleotides and oligoribonucleosides can include substituent groups for increasing binding affinity to complementary nucleic acid strand as well as substituent groups for increasing nuclease resistance. The oligomeric compounds are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to oligonucleotide therapeutics. Also included in the invention are mammalian ribonucleases, i.e., enzymes that degrade RNA, and substrates for such ribonucleases. Such a ribonuclease is referred to herein as a dsRNase, wherein “ds” indicates the RNase's specificity for certain double-stranded RNA substrates.
    Type: Grant
    Filed: October 25, 2002
    Date of Patent: October 7, 2008
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Stanley T. Crooke
  • Publication number: 20080207541
    Abstract: The present invention provides compositions and methods for the optimization of cleavage of RNA species by RNase H. In some embodiments, the invention provides oligonucleotides that possess two or more regions of differing conformation, and at least one transitional nucleobase positioned between the regions that is capable of modulating transfer of the helical conformation characteristic of the region bound to the 3?hydroxy thereof, to the region bound to the 5? hydroxyl thereof.
    Type: Application
    Filed: March 15, 2005
    Publication date: August 28, 2008
    Inventors: Michael T. Migawa, Walter F. Lima, Eric E. Swayze, Joshua Nichols, Hongjiang Wu, Thazha P. Prakash, Tadeusz Krzysztof Wyrzykiewicz, Balkrishen Bhat, Stanley T. Crooke
  • Patent number: 7339051
    Abstract: The present invention provides design and synthesis of oligomeric compounds and compositions that can be administered to reduce the activity of SARS virus in vivo or in vitro, to prevent or treat SARS virus-associated disease, to detect AARS virus, and to diagnose SARS virus-associated diseases.
    Type: Grant
    Filed: April 26, 2004
    Date of Patent: March 4, 2008
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Stanley T. Crooke, David J. Ecker, Rangarajan Sampath, Susan M. Freier, Christian Massire, Steven A. Hofstadler, Kristin Sannes Lowery, Eric E. Swayze, Brenda F. Baker, C. Frank Bennett
  • Patent number: 7255992
    Abstract: The present invention provides methods for rapid detection of bioagents for environmental and product testing. The methods can be used for testing air, water, soil, surfaces of buildings, containers, towers and the like, as well as testing of foodstuff and cosmetics.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: August 14, 2007
    Assignee: Isis Pharmaceuticals, Inc
    Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, Lawrence B. Blyn, Thomas A. Hall
  • Patent number: 7226739
    Abstract: The present invention provides methods for rapid forensic investigations by identification of bioagents associated with biowarfare and acts of terrorism or crime. The methods are also useful for epidemiological investigations by genotyping of bioagents.
    Type: Grant
    Filed: September 12, 2003
    Date of Patent: June 5, 2007
    Assignee: Isis Pharmaceuticals, Inc
    Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke, James C. Hannis
  • Patent number: 7217510
    Abstract: The present invention relates generally to the field of investigational bioinformatics and more particularly to secondary structure defining databases. The present invention further relates to methods for interrogating a database as a source of molecular masses of known bioagents for comparing against the molecular mass of an unknown or selected bioagent to determine either the identity of the selected bioagent, and/or to determine the origin of the selected bioagent. The identification of the bioagent is important for determining a proper course of treatment and/or irradication of the bioagent in such cases as biological warfare. Furthermore, the determination of the geographic origin of a selected bioagent will facilitate the identification of potential criminal identity.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: May 15, 2007
    Assignee: ISIS Pharmaceuticals, Inc.
    Inventors: David J. Ecker, Richard H. Griffey, Rangarajan Sampath, Steven A. Hofstadler, John McNeil, Stanley T. Crooke
  • Patent number: 6969763
    Abstract: Methods for the identification of compounds which modulate, either inhibit or stimulate, biomolecules are provided. Nucleic acids, especially RNAs are preferred substrates for such modulation. The present methods are particularly powerful in that they provide novel combinations of techniques which give rise to compounds, usually “small” organic compounds, which are highly potent modulators of RNA and other biomolecular activity. In accordance with preferred aspects of the invention, very large numbers of compounds may be tested essentially simultaneously to determine whether they are likely to interact with a molecular interaction site and modulate the activity of the biomolecule. Pharmaceuticals, veterinary drugs, agricultural chemicals, industrial chemicals, research chemicals and many other beneficial compounds may be identified in accordance with embodiments of this invention.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: November 29, 2005
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: David J. Ecker, Richard Griffey, Stanley T. Crooke, Ranga Sampath, Eric Swayze, Venkatraman Mohan, Steven Hofstadler, John McNeil